TY - JOUR
T1 - Current therapies and new developments in NASH
AU - Dufour, Jean François
AU - Anstee, Quentin M.
AU - Bugianesi, Elisabetta
AU - Harrison, Stephen
AU - Loomba, Rohit
AU - Paradis, Valerie
AU - Tilg, Herbert
AU - Wong, Vincent Wai Sun
AU - Zelber-Sagi, Shira
N1 - Publisher Copyright:
©
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Non-Alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.
AB - Non-Alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.
UR - http://www.scopus.com/inward/record.url?scp=85132796389&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2021-326874
DO - 10.1136/gutjnl-2021-326874
M3 - Review article
C2 - 35710299
AN - SCOPUS:85132796389
SN - 0017-5749
VL - 71
SP - 2123
EP - 2134
JO - Gut
JF - Gut
IS - 10
ER -